2nd February 2021
Budget reaction: Sanjiv Navangul, MD & CEO, Bharat Serums and Vaccines
www.zeebiz.com 2 Feb 2021:
Sanjiv Navangul, MD & CEO, Bharat Serums and Vaccines said, “The union budget has given a substantial increase to bolster the healthcare sector in India. Rs 35000 crore for COVID-19 vaccine and the commitment to the pneumococcal vaccine to be rolled out nationwide to avert child deaths is a massive boost. A well-spent allocation of Rs 64,000 crore under the new Atmanirbhar Swasthya Bharat Yojana scheme will show significant results thus labelling #healthyindia as an encouraging effort. And the infrastructural push will certainly create many more skilled jobs revitalizing the overall ecosystem.”
About BSV
BSV has been a pioneer in the development of blood components and therapeutic antibody products for infectious and non-infectious diseases. For over four decades, BSVL has focused on utilizing its scientific resources to develop several biological, biotechnology and pharmaceutical products to treat various types of diseases, contributing to preserve, protect and enhance the quality of life. We aim to be a leading biopharmaceutical company driven by people & science to set benchmarks in patient outcomes in Women’s Health, Critical Care & Emergency Medicine.
For more information, please contact:
Irawati Gowariker, BSV, Irawati.gowariker@bsvgroup.com